Extracellular Biocoordinated Zinc Nanofibers Inhibit Malignant Characteristics of Cancer Cell
Source abstract
Abstract
Inhibition of the heat shock proteins (HSPs) has been considered to be one of the promising strategies for cancer treatment. However, developing highly effective HSP inhibitors remains a challenge. Recent studies on the evolutionarily distinct functions between intracellular and extracellular HSPs (eHSPs) trigger a new direction with eHSPs as chemotherapeutic targets. Herein, the first engineered eHSP nanoinhibitor with high effectiveness is reported. The zinc-aspartic acid nanofibers have specific binding ability to eHSP90, which induces a decrease in the level of the tumor marker-gelatinases, consequently resulting in downregulation of the tumor-promoting inflammation nuclear factor-kappa B signaling, and finally inhibiting cancer cell proliferation, migration, and invasion; while they are harmless to normal cells. Our findings highlight the potential for cancer treatment by altering the key determinants that shape its ability to adapt and evolve using novel nanomaterials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Heat shock proteins research · Endoplasmic Reticulum Stress and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CAS Key Laboratory of Nanosystem and Hierarchical Fabrication, National Center for Nanoscience and Technology, Beijing 100190, China
School of Life Sciences, Jilin University, Changchun 130012, China
Funding
Chinese Academy of Sciences · Natural Science Foundation of Beijing Municipality · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences
References (38)
Show source-provided references
1. 10.1038/nrc171610.1038/nrc1716 ↗
2. 10.1016/j.tips.2014.09.00110.1016/j.tips.2014.09.001 ↗
3. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
4. 10.1158/1078-0432.CCR-11-100010.1158/1078-0432.CCR-11-1000 ↗
5. 10.1038/nrc288710.1038/nrc2887 ↗
6. 10.1016/j.canlet.2015.03.02510.1016/j.canlet.2015.03.025 ↗
7. 10.1016/S1470-2045(13)70169-410.1016/S1470-2045(13)70169-4 ↗
8. 10.3390/cancers602106510.3390/cancers6021065 ↗
9. 10.1021/jm500823a10.1021/jm500823a ↗
10. 10.1517/13543784.2014.90244210.1517/13543784.2014.902442 ↗
11. Sidera K. · Recent Pat. Anticancer Drug Discovery · 2014 · 9 · 1
12. 10.1038/sj.onc.121089710.1038/sj.onc.1210897 ↗
13. 10.1186/1471-2121-11-5110.1186/1471-2121-11-51 ↗
14. 10.1016/B978-0-12-407697-6.00005-210.1016/B978-0-12-407697-6.00005-2 ↗
15. 10.3322/caac.2119910.3322/caac.21199 ↗
16. 10.1002/adma.20140248910.1002/adma.201402489 ↗
17. 10.1038/nnano.2012.20710.1038/nnano.2012.207 ↗
18. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
19. 10.1021/nl400368v10.1021/nl400368v ↗
20. 10.1166/jnn.2011.475510.1166/jnn.2011.4755 ↗
21. 10.1002/smll.20090213210.1002/smll.200902132 ↗
22. 10.1073/pnas.02262689910.1073/pnas.022626899 ↗
23. 10.1016/S0753-3322(03)00081-710.1016/S0753-3322(03)00081-7 ↗
24. Millward D. J. · Am. J. Clin. Nutr. · 2008 · 87 · 157610.1093/ajcn/87.5.1576S ↗
25. 10.1016/j.addr.2009.07.00710.1016/j.addr.2009.07.007 ↗
26. 10.1021/ja908721t10.1021/ja908721t ↗
27. 10.1039/b925066b10.1039/b925066b ↗
28. 10.1021/ja102827f10.1021/ja102827f ↗
29. 10.1002/anie.20100820610.1002/anie.201008206 ↗
30. 10.1038/ncb113110.1038/ncb1131 ↗
31. 10.1074/jbc.M110.13934510.1074/jbc.M110.139345 ↗
32. 10.1126/science.107191410.1126/science.1071914 ↗
33. 10.1155/2012/84954110.1155/2012/849541 ↗
34. Kubinyi H. · 2007
35. 10.1002/smll.20140203810.1002/smll.201402038 ↗
36. 10.1172/JCI2587810.1172/JCI25878 ↗
37. 10.1021/nn504573u10.1021/nn504573u ↗
38. 10.2217/fon.09.3010.2217/fon.09.30 ↗